Results 81 to 90 of about 12,380 (194)

Switching Acute Coronary Syndrome Patients From Prasugrel to Clopidogrel

, 2013
ObjectivesThis study sought to assess the consequences of switching prasugrel to clopidogrel on platelet inhibition and clinical outcomes after an acute coronary syndrome (ACS).BackgroundMany ACS patients are switched from prasugrel to clopidogrel within
Barthélémy, Olivier, Vignalou, Jean-Baptiste, Abtan, Jérémie, Kerneis, Mathieu, Cayla, Guillaume, Beygui, Farzin, Martin, Réjane, Montalescot, Gilles, Collet, Jean-Philippe, O'Connor, Stephen A., Brugier, Delphine, Silvain, Johanne   +11 more
core   +1 more source

Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study. [PDF]

, 2015
OBJECTIVES The aim of this study was to assess the safety of the concurrent administration of a clopidogrel and prasugrel loading dose in patients undergoing primary percutaneous coronary intervention.
Roffi, Marco, Mach, Francois, Ostojic, Miodrag C., Jüni, Peter, Meier, Bernard, Klingenberg, Roland, Carballo, David, Auer, Reto, Stefanini, Giulio, Engstrøm, Thomas, Matter, Christian M., Gencer, Baris, Stefanini, Giulio G., Tüller, David, Kelbæk, Henning, Meier, Bernhard, Heg, Dik, Lüscher, Thomas F, Baumbach, Andreas, Windecker, Stephan, Rodondi, Nicolas, Lüscher, Thomas F., Ostojic, Miodrag, Stefanini, Giulio G, Matter, Christian M, Zanchin, Thomas, Räber, Lorenz, Moschovitis, Aris, von Birgelen, Clemens, Kelbaek, Henning   +29 more
core   +1 more source

Prasugrel hydrochloride for the treatment of sickle cell disease

, 2017
INTRODUCTION: Therapeutic options for sickle cell disease (SCD) are limited and, currently, only one drug (hydroxyurea) has FDA approval for the treatment of adult SCD.
Conran, Nicola, David C. Rees, Nicola Conran, Rees, David C   +3 more
core   +1 more source

TRITON and Beyond: New Insights into the Profile of Prasugrel.

, 2011
Prasugrel, a third-generation thienopyridine antiplatelet agent, demonstrated superior efficacy to clopidogrel but with an increased risk of bleeding in the phase III pivotal registration Trial to Assess Improvement in Therapeutic Outcomes by Optimizing ...
Erlinge, David,, Joseph A. Jakubowski, Jakubowski, Joseph A, Close, Sandra L, David Erlinge, Erlinge, David, Sandra L. Close, Leishman, Amy G, Jeffrey S. Riesmeyer, Lund University., Amy G. Leishman, Riesmeyer, Jeffrey S   +11 more
core   +1 more source

Impact of Society Guidelines on Trends in Use of Newer P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Over the past decade, major society guidelines have recommended the use of newer P2Y12 inhibitors over clopidogrel for those undergoing percutaneous coronary intervention for acute coronary syndrome.
Mohamed O. Mohamed, Evangelos Kontopantelis, Mirvat Alasnag, Leila Abid, Amitava Banerjee, Andrew S. P. Sharp, Christos Bourantas, Alex Sirker, Nick Curzen, Mamas A. Mamas   +9 more
doaj   +1 more source

Concomitant Polymorphism of Prasugrel Hydrochloride in Reactive Crystallization

, 2016
Concomitant polymorphism of prasugrel hydrochloride was investigated in reactive batch crystallization experiments at 20 and 40 °C. The solubility of prasugrel hydrochloride form I and form II was experimentally determined.
Jingkang Wang (1758835), Chuang Xie (1755553), Wei Du (88790), Baohong Hou (1514521), Ying Bao (267477), Hongxun Hao (1479568), Qiuxiang Yin (1514518), Wei Chen (23863), Junbo Gong (400138)   +8 more
core   +1 more source

The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease

, 2014
CYP2C19 genotype has been shown to impact response to clopidogrel 75-mg but not prasugrel 10-mg. Here, we assessed effects of CYP2C19 metaboliser status on pharmacokinetics (PK) and pharmacodynamic (PD) responses to prasugrel 5-mg and 10-mg and ...
Small, David,, Duvvuru, Suman,, Angiolillo, Dominick J.,, Gurbel, Paul A., Brown, Patricia B., Gurbel, Paul A.,, ten Berg, Jurrien M.,, Angiolillo, Dominick J., James, Stefan, Sundseth, Scott,, ten Berg, Jurrien M., Jakubowski, Joseph A.,, Tantry, Udaya S., Svensson, Peter,, Jakubowski, Joseph A., Moser, Brian A.,, Small, David, Walker, Joseph R.,, Duvvuru, Suman, Tantry, Udaya S.,, James, Stefan K.,, Lindahl, Tomas, Sundseth, Scott, Erlinge, David,, Lindahl, Tomas,, Winters, Kenneth J., Lindahl, Tomas L., Bergmeijer, Thomas O., Brown, Patricia B.,, Moser, Brian A., Bergmeijer, Thomas O.,, Erlinge, David, James, Stefan,, Walker, Joseph R., Lund University., Svensson, Peter, Winters, Kenneth J.,   +36 more
core   +2 more sources

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention

Open Heart, 2019
Background There is a paucity of real-world outcome data comparing clopidogrel, prasugrel and ticagrelor in primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI).
Jim McLenachan, Christopher Malkin, Daniel J Blackman, John Greenwood, Stephen Wheatcroft, Paul Baxter, Arvindra Krishnamurthy, Claire Keeble, Michelle Anderson, Kathryn Somers, Natalie Burton-Wood, Charlotte Harland, Jonathan Blaxill   +12 more
doaj   +1 more source

Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis

BMC Cardiovascular Disorders, 2018
Background Due to limitations associated with clopidogrel following percutaneous coronary intervention (PCI), other newer oral anti-platelet agents are being studied.
Pravesh Kumar Bundhun, Feng Huang
doaj   +1 more source

Ticagrelor vs prasugrel for acute coronary syndrome in routine care [PDF]

Importance In patients with acute coronary syndrome (ACS) undergoing invasive treatment, ticagrelor and prasugrel are guideline-recommended P2Y12 receptor inhibitors.
Kessler, Thorsten, Xhepa, Erion, Meyer-Lindemann, Ulrike, Pugach, Irina, Kastrati, Adnan, Wiebe, Jens, Sager, Hendrik B., Joner, Michael, Manea, Iulian, Graesser, Christian, Kufner, Sebastian, Krefting, Johannes, Storz, Theresa, Bongiovanni, Dario, Krase, Peter, Krüger, Nils, Dreischulte, Tobias, Schunkert, Heribert, Starnecker, Fabian, Trenkwalder, Teresa, Offenborn, Frank, Frieß, Christian, Dutsch, Alexander, Chen, Zhifen, Cassese, Salvatore, von Scheidt, Moritz, Schmieder, Raphael, Gueldener, Ulrich   +27 more
core   +1 more source